Searched for
GLENMARK GUIDANCE
Novo Nordisk’s weight-loss drug patent loss sparks a ‘gold rush’ for generic drugmakersIndia's weight-loss drug market is seeing a major shift. Generic versions of Novo Nordisk's semaglutide are now available at lower prices. ...- Centre steps up oversight on GLP-1 drugs amid concerns over 'improper' practicesIndia's drug regulator is increasing oversight of GLP-1 weight loss drugs. Inspections across 49 entities revealed violations like unauthor...
- GLP-1 rush: Pharma, food firms eye tie-ups for weight-loss boomAffordable weight-loss jabs are here. Drugmakers and food companies are partnering. They will offer special nutrition products. These are f...
- Glenmark Q3 profit rises 16% on strong India, US performanceGlenmark Pharmaceuticals posted 16% growth in December-quarter profit on strong India formulations demand, improved North America performan...
- No revision, Glenmark Pharma sticking to full-year guidance: VS ManiVS Mani, CFO of Glenmark Pharma, discusses the company's strong performance in FY25 with an average of Rs 1,100 crore per quarter. Challeng...
- Glenmark Pharmaceutical Inc recalls ranitidine tablets in USThe tablets are being recalled because of the presence or potential presence of N-nitrosodimethylamine (NDMA) levels above the acceptable d...
- Desi pharma companies see big business in competitive genericsThe opportunity for domestic companies could cumulatively fetch up to a billion dollars in sales.
- Hold Glenmark Pharma, target Rs 595: Emkay GlobalHold Glenmark Pharmaceuticals Ltd. at a price target of Rs 595.0 .
- Buzzing stocks: PCJ’s zigzag show, midair turmoil for aviation stocksForeign outflows continued but domestic inflows remained strong and helped the indices cap losses.
- Glenmark Pharma surges 7% as brokerages stay upbeat post Q3 numbersBofa-ML believes that the growth momentum in the US geography is likely to sustain beyond 6-month exclusivity for cholesterol lowering drug...
- A bear phase for pharma pack! 10 stocks fall up to 40% from highsNifty Pharma index is down over 20% from its 52-week high of 13,753.50, which indicates a bearish phase for the index. Glenmark, Cipla are ...
- Neutral on Glenmark Pharma with a a target at Rs 900: Motilal OswalThe US business holds the key for GNP to achieving management's growth guidance
- There is a slowdown in IT services space: Deepak Shenoy, Capital MindThere is some issue with IT in general as IT services exports have been falling and this is an event that will also come into RBI data soon
- Glenmark climbs 3% on bullish management guidanceShares of Glenmark gained about 3 per cent in Wednesday's trade after the company provided a bullish guidance of 18-20 per cent growing in ...
- Glenmark, Aurobindo should be part of core portfolio: Ajay BodkePharma stocks are trading at extremely high valuations and, thus, could especially be vulnerable to any disappointment, says Bodke.
- Glenmark Pharma aims at Rs 5,000 crore revenue during FY13, focus on USGlenmark Pharmaceuticals today said it is aiming for up to 30 per cent growth in revenues this fiscal to touch Rs 5,000 crore.
- Glenmark Pharmaceuticals may be rerated due to attractive valuations, strong performanceAided by robust growth from its key businesses and geographies, Glenmark managed to show a strong topline growth of 34% year-on-year in the...
- Glenmark Pharma posts FY11 net at Rs 457.83 crGlenmark Pharmaceuticals today posted a consolidated net profit of Rs 457.83 crore for the year ended March 31, 2011.
- Medicis deal, generic biz to boost financialsRecent developments could well be a pointer to better days ahead for Glenmark Pharma which has had a relatively poor performance in the pas...
- Analysts' picks : Glenmark PharmaCiti has maintained a ‘buy’ rating on Glenmark Pharmaceuticals after the company maintained its revenue and PAT guidance for FY09-10.
Load More
